
Annual report 2025
added 04-04-2026
Alcon Financial Statements 2011-2026 | ALC
Annual Financial Statements Alcon
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
- | - | - | - | 42.6 B | 32.1 B | 27.5 B | - | 40.3 B | - | - | - | - | - | - |
Shares |
- | - | - | - | 490 M | 488 M | 488 M | - | 489 M | - | - | - | - | - | - |
Historical Prices |
87.1 | 92.9 | 86.5 | 82.4 | 86.9 | 65.7 | 56.3 | - | - | - | - | - | - | - | - |
Net Income |
- | - | - | - | 376 M | -531 M | -656 M | -227 M | 256 M | -170 M | - | - | - | - | - |
Revenue |
10.4 B | 9.91 B | 9.46 B | 8.72 B | 8.29 B | 6.83 B | 7.51 B | 7.15 B | 6.79 B | 6.6 B | - | - | - | - | - |
Cost of Revenue |
- | - | - | - | 3.58 B | 3.83 B | 3.72 B | 3.96 B | 3.59 B | - | - | - | - | - | - |
Gross Profit |
5.74 B | 5.51 B | 5.25 B | 4.75 B | 4.65 B | 2.94 B | 3.66 B | 3.19 B | 3.2 B | 3.13 B | - | - | - | - | - |
Operating Income |
- | - | - | - | 580 M | -482 M | -187 M | -248 M | -77 M | - | - | - | - | - | - |
Interest Expense |
204 M | 192 M | 189 M | 134 M | 120 M | 124 M | 113 M | 24 M | 27 M | - | - | - | - | - | - |
EBITDA |
- | - | - | - | 580 M | -482 M | -187 M | -248 M | -77 M | 1.29 B | - | - | - | - | - |
Operating Expenses |
- | - | - | - | - | 3.37 B | 3.85 B | 3.44 B | 3.28 B | 3.1 B | - | - | - | - | - |
General and Administrative Expenses |
- | - | - | - | 251 M | - | 2.8 B | 2.79 B | 2.6 B | 2.53 B | - | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement Alcon
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
- | - | - | - | - | - | 493 M | - | - | - | 489 M | - | - | - | 488 M | - | - | - | 488 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
- | - | - | - | - | - | 151 M | - | - | - | -422 M | - | - | - | -390 M | - | - | - | 15 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
- | - | - | - | - | - | 2.11 B | - | - | - | 1.21 B | - | - | - | 1.9 B | - | - | - | 1.82 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
- | - | - | - | - | - | 875 M | - | - | - | 854 M | - | - | - | 922 M | - | - | - | 942 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | 1.22 B | - | - | - | 345 M | - | - | - | 947 M | - | - | - | 878 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
- | - | - | - | - | - | 229 M | - | - | - | -466 M | - | - | - | -53 M | - | - | - | 38 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
- | - | - | - | - | - | 30 M | - | - | - | 30 M | - | - | - | 35 M | - | - | - | 6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
- | - | - | - | - | - | 229 M | - | - | - | -466 M | - | - | - | -53 M | - | - | - | 38 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
- | - | - | - | - | - | 69 M | - | - | - | 62 M | - | - | - | 54 M | - | - | - | 49 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Main types of financial statements Alcon ALCFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting Alcon plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
The Cooper Companies
COO
|
$ 70.29 | 0.17 % | $ 14 B | ||
|
Atrion Corporation
ATRI
|
- | - | $ 810 M | ||
|
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | ||
|
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | ||
|
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | ||
|
Baxter International
BAX
|
$ 16.65 | -0.18 % | $ 8.54 B | ||
|
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | ||
|
BioLife Solutions
BLFS
|
$ 19.27 | -1.23 % | $ 888 M | ||
|
AtriCure
ATRC
|
$ 29.19 | 0.41 % | $ 1.39 B | ||
|
electroCore
ECOR
|
$ 7.04 | 3.53 % | $ 59.7 K | ||
|
Ekso Bionics Holdings
EKSO
|
$ 9.75 | 3.72 % | $ 23.7 M | ||
|
Glaukos Corporation
GKOS
|
$ 116.69 | 3.48 % | $ 5.65 B | ||
|
Haemonetics Corporation
HAE
|
$ 58.46 | 2.87 % | $ 2.94 B | ||
|
Harvard Bioscience
HBIO
|
$ 5.53 | 6.35 % | $ 245 M | ||
|
ICU Medical
ICUI
|
$ 122.99 | -0.26 % | $ 3.03 B | ||
|
InfuSystem Holdings
INFU
|
$ 9.43 | 1.51 % | $ 195 M | ||
|
iRhythm Technologies
IRTC
|
$ 117.22 | 0.36 % | $ 3.75 B | ||
|
Isoray
ISR
|
- | 0.03 % | $ 108 M | ||
|
Intuitive Surgical
ISRG
|
$ 452.58 | 0.11 % | $ 162 B | ||
|
Repro Med Systems
KRMD
|
$ 4.26 | -1.39 % | $ 197 M | ||
|
LeMaitre Vascular
LMAT
|
$ 109.16 | 0.62 % | $ 2.47 B | ||
|
Masimo Corporation
MASI
|
$ 178.49 | -0.06 % | $ 9.51 B | ||
|
Microbot Medical
MBOT
|
$ 2.36 | -1.67 % | $ 108 M | ||
|
Milestone Scientific
MLSS
|
$ 0.29 | 1.9 % | $ 23.8 M | ||
|
Merit Medical Systems
MMSI
|
$ 67.81 | 0.16 % | $ 4.01 B | ||
|
Envista Holdings Corporation
NVST
|
$ 25.81 | - | $ 4.34 B | ||
|
Predictive Oncology
POAI
|
- | - | $ 31.1 M | ||
|
Pro-Dex
PDEX
|
$ 48.53 | -6.08 % | $ 160 M | ||
|
Pulse Biosciences
PLSE
|
$ 22.94 | -0.26 % | $ 1.55 B | ||
|
ResMed
RMD
|
$ 224.93 | 0.37 % | $ 32.9 B | ||
|
Retractable Technologies
RVP
|
$ 0.71 | 2.98 % | $ 21.3 M | ||
|
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | ||
|
STAAR Surgical Company
STAA
|
$ 20.96 | 3.71 % | $ 1.04 B | ||
|
STERIS plc
STE
|
$ 219.97 | 0.58 % | $ 21.7 B | ||
|
Stereotaxis
STXS
|
$ 1.88 | -0.53 % | $ 171 M | ||
|
Teleflex Incorporated
TFX
|
$ 115.04 | -2.35 % | $ 5.13 B | ||
|
Utah Medical Products
UTMD
|
$ 62.93 | -0.3 % | $ 204 M | ||
|
West Pharmaceutical Services
WST
|
$ 256.85 | 0.8 % | $ 18.6 B | ||
|
DENTSPLY SIRONA
XRAY
|
$ 11.64 | 0.09 % | $ 2.32 B | ||
|
AngioDynamics
ANGO
|
$ 9.84 | -4.56 % | $ 402 M | ||
|
Becton, Dickinson and Company
BDX
|
$ 155.32 | 0.52 % | $ 44.7 B | ||
|
Nephros
NEPH
|
$ 2.86 | -0.35 % | $ 29.7 M | ||
|
OraSure Technologies
OSUR
|
$ 3.08 | - | $ 226 M | ||
|
Repligen Corporation
RGEN
|
$ 116.95 | -0.7 % | $ 6.52 M |